Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of oral folinic acid rescue on pemetrexed-induced neutropenia and toxicity
2022-502345-10-00Phase 4Completed
- Sponsor
- Amphia Ziekenhuis
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of folinic acid in non-small cell lung cancer (NSCLC), mesothelioma and thymoma (2 arms), sponsored by Amphia Ziekenhuis. Primary endpoint: Neutrophil count at day 8–10. Started Feb 2023; status: completed.
02
Drugs
folinic acid
03
Conditions
non-small cell lung cancer (NSCLC)mesotheliomathymoma
Beyond the preview
Go deeper on 2022-502345-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502345-10-00.